# Mutation-specific Therapy for the Long QT Syndrome

> **NCT04581408** · PHASE2 · COMPLETED · sponsor: **Istituto Auxologico Italiano** · enrollment: 16 (actual)

## Conditions studied

- Long QT Syndrome

## Interventions

- **DRUG:** Lumacaftor / Ivacaftor, Orkambi® Oral Tablet

## Key facts

- **NCT ID:** NCT04581408
- **Lead sponsor:** Istituto Auxologico Italiano
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-15
- **Primary completion:** 2025-04-15
- **Final completion:** 2025-04-15
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2025-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04581408

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04581408, "Mutation-specific Therapy for the Long QT Syndrome". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04581408. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*